4.4 Article

Cell-Free Tumor DNA Dominant Clone Allele Frequency Is Associated With Poor Outcomes in Advanced Biliary Cancers Treated With Platinum-Based Chemotherapy

Journal

JCO PRECISION ONCOLOGY
Volume 6, Issue 1, Pages -

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1200/PO.21.00274

Keywords

-

Categories

Funding

  1. Mayo Clinic Hepatobiliary SPORE [P50CA 210964]
  2. National Institute of Health (NIH) [CA195764]
  3. National Cancer Institute (NCI) [CA090628, CA234324]
  4. SPORE Project Award [5P50CA210964-03]
  5. SPORE Supplement Award [3P50CA210964-02S1]
  6. Mayo Clinic Center for Individualized Medicine (CIM) Precision Cancer Therapeutics Program
  7. Mayo Clinic Cancer Center

Ask authors/readers for more resources

This study aimed to evaluate the prognostic value of pretreatment circulating tumor DNA (ctDNA) in metastatic biliary tract cancers (BTCs) treated with platinum-based chemotherapy. The results showed that DCAF > 3% was associated with worse overall survival (OS). Stratifying DCAF into quartiles, DCAF > 10% was significantly related to worse progression-free survival (PFS) and OS. Each 1% increase in ctDNA was associated with a decrease in survival probabilities.
PURPOSE This investigation sought to evaluate the prognostic value of pretreatment of circulating tumor DNA (ctDNA) in metastatic biliary tract cancers (BTCs) treated with platinum-based first-line chemotherapy treatment. MATERIALS AND METHODS We performed a retrospective analysis of 67 patients who underwent ctDNA testing before platinum-based chemotherapy for first-line treatment for metastatic BTC. For analysis, we considered the detected gene with highest variant allele frequency as the dominant clone allele frequency (DCAF). Results of ctDNA analysis were correlated with patients' demographics, progression-free survival (PFS), and overall survival (OS). RESULTS The median age of patients was 67 (27-90) years. Fifty-four (80.6%) of 67 patients evaluated had intrahepatic cholangiocarcinoma; seven had extrahepatic cholangiocarcinoma, and six gallbladder cancers. Forty-six (68.6%) of the patients were treated with cisplatin plus gemcitabine, and 16.4% of patients received gemcitabine and other platinum (carboplatin or oxaliplatin) combinations, whereas 15% of patients were treated on a clinical trial with gemcitabine and cisplatin plus additional agents (CX4945, PEGPH20, or nab-paclitaxel). TP53, KRAS, FGFR2, ARID1A, STK11, and IDH1 were the genes with highest frequency as DCAF. The median DCAF was 3% (0%-97%). DCAF > 3% was associated with worse OS (median OS: 10.8 v 18.8 months, P = .032). Stratifying DCAF in quartiles, DCAF > 10% was significantly related to worse PFS (median PFS: 3 months, P = .014) and worse OS (median OS: 7.0 months, P = .001). Each 1% increase in ctDNA was associated with a hazard ratio of 13.1 in OS when adjusting for subtypes, metastatic sites, size of largest tumor, age, sex, and CA19-9. CONCLUSION DCAF at diagnosis of advanced BTC can stratify patients who have worse outcomes when treated with upfront platinum-based chemotherapy. Each increase in %ctDNA decreases survival probabilities.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available